Alnylam Pharmaceuticals
ALNY
#622
Rank
โ‚น2.688 T
Marketcap
โ‚น20,844
Share price
2.75%
Change (1 day)
38.42%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -โ‚น337.20

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -โ‚น349.05. In 2022 the company made an earnings per share (EPS) of -โ‚น788.97 a decrease over its 2021 EPS that were of -โ‚น611.47.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-โ‚น337.20-57.26%
2022-โ‚น788.9729.03%
2021-โ‚น611.47-3.36%
2020-โ‚น632.71-8.48%
2019-โ‚น691.317.67%
2018-โ‚น642.0539.74%
2017-โ‚น459.4612.94%
2016-โ‚น406.8038.84%
2015-โ‚น293.00-32.88%
2014-โ‚น436.52259.44%
2013-โ‚น121.45-31.25%
2012-โ‚น176.6552.94%
2011-โ‚น115.5030.77%
2010-โ‚น88.32-8.77%
2009-โ‚น96.8278.13%
2008-โ‚น54.35-70.78%
2007-โ‚น185.9999.09%
2006-โ‚น93.42-43.88%
2005-โ‚น166.46-82.33%
2004-โ‚น942.13-59.23%
2003-โ‚น2,311

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-โ‚น144.38-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น3,173-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น664.98 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น22.93-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น143.53-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น317.63-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚น270.09-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-โ‚น169.85-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel